Dementia and Geriatric Cognitive Disorders

Original Research Article

The Alzheimer Variant of Lewy Body Disease: A Pathologically Confirmed Case-Control Study

Perneczky R.a · Mösch D.a · Neumann M.b · Kretzschmar H.b · Müller U.c · Busch R.d · Förstl H.a · Kurz A.a

Author affiliations

aKlinik und Poliklinik für Psychiatrie und Psychotherapie der Technischen Universität München, bInstitut für Neuropathologie der Ludwig-Maximilians-Universität München, München, cInstitut für Humangenetik der Justus-Liebig-Universität Giessen, Giessen, dInstitut für Medizinische Statistik und Epidemiologie der Technischen Universität München, München, Deutschland

Keywords: Alzheimer-type dementiaLewy body dementiaHistopathology

Related Articles for ""
Dement Geriatr Cogn Disord 2005;20:89–94
https://doi.org/10.1159/000086472

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Received: January 29, 2005
Published online: August 19, 2005
Issue release date: August 2005

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 5

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Abstract

The objective of the study was to identify clinical features that distinguish patients with dementia with Lewy bodies (DLB), who were classified as Alzheimer’s disease (AD) patients, from patients with AD. We examined a group of 27 patients from our memory clinic, originally diagnosed with AD, of whom 6 were postmortem found to have DLB. For the present study, we compared cognitive, noncognitive and neurological symptoms between the two groups. We found that there were no differences on ratings of dementia and scales for activities of daily living. Patients with DLB performed better on the MMSE and the memory subtest of the CAMCOG, but there was no difference in any other cognitive domain. Furthermore, genetic risk factors, including family history of dementia or allele frequency of the apolipoprotein ε4, did not discriminate between the two groups, and there were no differences on CCT scans. Taken together, our findings suggest that Lewy body pathology may be present in patients who do not show the typical clinical features which distinguish DLB from AD.

© 2005 S. Karger AG, Basel



Related Articles:

References

  1. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M: The Lewy body variant of Alzheimer’s disease: A clinical and pathologic entity. Neurology 1990;40:1–8.
  2. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK: Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119–139.
  3. Stern Y, Jacobs D, Goldman J, Gomez-Tortosa E, Hyman B T, Liu Y, Troncoso J, Marder K, Tang MX, Brandt J, Albert M: An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol 2001;58:460–465.
  4. Kosaka K, Yoshimura M, Ikeda K, Budka H: Diffuse type of Lewy body disease: Progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree – a new disease? Clin Neuropathol 1984;3:185–192.
  5. Lennox G, Lowe J, Morrell K, Landon M, Mayer RJ: Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989;52:67–71.
  6. Dickson DW, Ruan D, Crystal H, Mark MH, Davies P, Kress Y, Yen SH: Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: Light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 1991;41:1402–1409.
  7. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, de-Vos RAI, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
  8. Verghese J, Crystal HA, Dickson D W, Lipton RB: Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999;53:1974–1982.
  9. Dilling H, Mombour W, Schmidt M H, Schulte-Markwort E (eds): Weltgesundheitsorganisation: Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V(F) Forschungskriterien. Bern, Huber, 1994.
  10. Kurz A, Haupt M, Pollmann S, Romero B: Alzheimer’s disease: Is there evidence of phenomenological subtypes? Dementia 1992;3:320–327.
  11. Kurz A, Lautenschlager N, Haupt M, Zimmer R, Von-Thülen B, Altlandt K, Lauter H, Müller U: Das Apolipoprotein-E-ε4-Allel ist ein Risikofaktor für die Alzheimer-Krankheit mit frühem und spätem Beginn. Nervenarzt 1994;65:774–779.
  12. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R: CAMDEX. A standardized instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698–709.
  13. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and the senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797–811.
  14. Reisberg B, Ferris SH, de-Leon M, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136–1139.
  15. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
  16. McKhann G, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  17. Rasmussen DX, Brandt J, Steele C, Hedreen JC, Troncoso JC, Folstein MF: Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis Assoc Disord 1996;10:180–188.
  18. McKeith IG, Perry RH, Fairbairn A: Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22:911–922.
  19. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–486.
  20. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–259.
  21. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ: Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol 2001;58:1803–1809.
  22. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I: Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002;61:935–946.
  23. Kurz A, Egensperger R, Haupt M, Lautenschlager N, Romero B, Graeber MB, Müller U: Apolipoprotein E allele ε4, cognitive decline, and deterioration of everyday performance in Alzheimer’s disease. Neurology 1996;47:440–443.
  24. Norusis MJ: SPSS Statistical Package for the Social Sciences. Chicago, SPSS, 1994.
  25. Förstl H, Burns A, Luthert P, Cairns N, Levy R: The Lewy-Body variant of Alzheimer’s disease. Br J Psychiatry 1993;162:385–392.
  26. Ballard CG, Jacoby R, Del Ser T, Khan MN, Munoz DG, Holmes C, Nagy Z, Perry EK, Joachim C, Jaros E, O’Brien JT, Perry RH, McKeith IG: Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry 2004;161:843–849.
  27. Ballard C, McKeith I, Harrison R, O’Brien J, Thompson P, Lowery K, Perry R, Ince P: A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer’s disease. Int Psychogeriatr 1997;9:381–388.
  28. Rockwell E, Choure J, Galasko D, Olichney J, Jeste DV: Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: Comparison of matched groups with autopsy-confirmed diagnoses. Int J Geriatr Psychiatry 2000;15:819–823.
  29. Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J: Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol 2000;57:347–351.
  30. Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR, Hodges JR: Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001;70:157–164.
  31. Walker MP, Ayre GA, Perry EK, Wesnes K, McKeith IG, Tovee M, Edwardson JA, Ballard CG: Quantification and characterization of fluctuating cognition in dementia with Lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord 2000;11:327–335.
  32. Ballard C, O’Brien J, Gray A, Cormack F, Ayre G, Rowan E, Thompson P, Bucks R, McKeith I, Walker M, Tovee M: Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2001;58:977–982.
  33. Ballard C, Walker M, O’Brien J, Rowan E, McKeith I: The characterisation and impact of ‘fluctuating’ cognition in dementia with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry 2001;16:494–498.
  34. Galasko D, Saitoh T, Xia Y, Thal LJ, Katzman R, Hill LR, Hansen L: The apolipoprotein E allele ε4 is overrepresented in patients with the Lewy body variant of Alzheimer’s disease. Neurology 1994;44:1950–1951.
  35. Lippa CF, Smith TW, Saunders AM, Crook R, Pulaski-Salo D, Davies P, Hardy J, Roses AD, Dickson D: Apolipoprotein E genotype and Lewy body disease. Neurology 1995;45:97–103.
  36. Singleton AB, Wharton A, O’Brien KK, Walker MP, McKeith I G, Ballard CG, O’Brien J, Perry RH, Ince PG, Edwardson JA, Morris CM: Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002;14:167–175.
  37. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, McKeith IG, O’Brien JT: Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643–649.
  38. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE: Alzheimer’s disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358–365.
  39. Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, Itoh M, Shin RW, Trojanowski JQ, Sasaki H: Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000;162:247–256.
  40. Middelkoop HA, van der Flier WM, Burton EJ, Lloyd AJ, Paling S, Barber R, Ballard C, McKeith IG, O’Brien JT: Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 2001;57:2117–2120.
  41. O’Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, Gholkar A, Crum WR, Rossor MN, Fox NC: Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001;56:1386–1388.
  42. Mirzaei S, Knoll P, Koehn H, Bruecke T: Assessment of diffuse Lewy body disease by 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET). BMC Nucl Med 2003;3:1.
  43. Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Hu XS, Takeda A, Itoh M, Sasaki H: (18F)FDG-PET study in dementia with Lewy bodies and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:447–456.
  44. Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, Poewe W, Ransmayr G: Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320–325.
  45. Kanemaru K, Kameda N, Yamanouchi H: Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000;54:1875–1876.
  46. Tschampa HJ, Schulz-Schaeffer W, Wiltfang J, Poser S, Otto M, Neumann M, Kretzschmar HA: Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2001;56:576.
  47. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F, Phospho-Tau International Study G: CSF phosphorylated tau is a possible marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001;22:77–78.

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Received: January 29, 2005
Published online: August 19, 2005
Issue release date: August 2005

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 5

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2005, Vol.20, No. 2-3

August 2005

Article

Recommend This
TOP